Advances in the targeted theragnostics of osteomyelitis caused by Staphylococcus aureus
- PMID: 38834761
- DOI: 10.1007/s00203-024-04015-2
Advances in the targeted theragnostics of osteomyelitis caused by Staphylococcus aureus
Abstract
Bone infections caused by Staphylococcus aureus may lead to an inflammatory condition called osteomyelitis, which results in progressive bone loss. Biofilm formation, intracellular survival, and the ability of S. aureus to evade the immune response result in recurrent and persistent infections that present significant challenges in treating osteomyelitis. Moreover, people with diabetes are prone to osteomyelitis due to their compromised immune system, and in life-threatening cases, this may lead to amputation of the affected limbs. In most cases, bone infections are localized; thus, early detection and targeted therapy may prove fruitful in treating S. aureus-related bone infections and preventing the spread of the infection. Specific S. aureus components or overexpressed tissue biomarkers in bone infections could be targeted to deliver active therapeutics, thereby reducing drug dosage and systemic toxicity. Compounds like peptides and antibodies can specifically bind to S. aureus or overexpressed disease markers and combining these with therapeutics or imaging agents can facilitate targeted delivery to the site of infection. The effectiveness of photodynamic therapy and hyperthermia therapy can be increased by the addition of targeting molecules to these therapies enabling site-specific therapy delivery. Strategies like host-directed therapy focus on modulating the host immune mechanisms or signaling pathways utilized by S. aureus for therapeutic efficacy. Targeted therapeutic strategies in conjunction with standard surgical care could be potential treatment strategies for S. aureus-associated osteomyelitis to overcome antibiotic resistance and disease recurrence. This review paper presents information about the targeting strategies and agents for the therapy and diagnostic imaging of S. aureus bone infections.
Keywords: S. aureus; Bone targeting agents; Host-directed therapy; Osteomyelitis; Targeting S.aureus; Targeting localized infection.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
A Diagnostic Serum Antibody Test for Patients With Staphylococcus aureus Osteomyelitis.Clin Orthop Relat Res. 2015 Sep;473(9):2735-49. doi: 10.1007/s11999-015-4354-2. Epub 2015 May 27. Clin Orthop Relat Res. 2015. PMID: 26013151 Free PMC article.
-
Antibiotic delivery from bone-targeted mesoporous silica nanoparticles for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus.Acta Biomater. 2022 Dec;154:608-625. doi: 10.1016/j.actbio.2022.10.039. Epub 2022 Oct 28. Acta Biomater. 2022. PMID: 36341887
-
Mechanisms of Antibiotic Failure During Staphylococcus aureus Osteomyelitis.Front Immunol. 2021 Feb 12;12:638085. doi: 10.3389/fimmu.2021.638085. eCollection 2021. Front Immunol. 2021. PMID: 33643322 Free PMC article. Review.
-
Repurposing the Nonsteroidal Anti-inflammatory Drug Diflunisal as an Osteoprotective, Antivirulence Therapy for Staphylococcus aureus Osteomyelitis.Antimicrob Agents Chemother. 2016 Aug 22;60(9):5322-30. doi: 10.1128/AAC.00834-16. Print 2016 Sep. Antimicrob Agents Chemother. 2016. PMID: 27324764 Free PMC article.
-
A comprehensive review of pathology and treatment of staphylococcus aureus osteomyelitis.Clin Exp Med. 2025 Apr 29;25(1):131. doi: 10.1007/s10238-025-01595-1. Clin Exp Med. 2025. PMID: 40299136 Free PMC article. Review.
Cited by
-
In vitro assessment of the osteogenic and antibacterial capabilities of Mg-MOF particles with encapsulated Levofloxacin within polydopamine.Sci Rep. 2025 Jul 23;15(1):26828. doi: 10.1038/s41598-025-13056-6. Sci Rep. 2025. PMID: 40702217 Free PMC article.
References
-
- Abatángelo V, Peressutti Bacci N, Boncompain CA, Amadio AA, Carrasco S, Suárez CA, Morbidoni HR (2017) Broad-range lytic bacteriophages that kill Staphylococcus aureuslocal field strains. PLoS ONE 12(7). https://doi.org/10.1371/journal.pone.0181671
-
- Abdulrehman T (2020) Targeted Nanoparticle Therapy for Osteomyelitis (Order No. 28257453). Available from ProQuest Dissertations & Theses Global. (2616294454). In PQDT - Global. https://www.proquest.com/dissertations-theses/targeted-nanoparticle-ther...
-
- Abed N, Saïd-Hassane F, Zouhiri F, Mougin J, Nicolas V, Desmaële D, Gref R, Couvreur P (2015) An efficient system for intracellular delivery of beta-lactam antibiotics to overcome bacterial resistance. Sci Rep 5. https://doi.org/10.1038/srep13500
-
- Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM (2011) Phage treatment of human infections. Bacteriophage 1(2):66–85. https://doi.org/10.4161/bact.1.2.15845 - DOI - PubMed - PMC
-
- Abushahba MF, Mohammad H, Seleem MN (2016) Targeting Multidrug-resistant staphylococci with an anti-rpoa peptide nucleic acid conjugated to the HIV-1 TAT cell penetrating peptide. Mol Therapy Nucleic Acids 5:e339. https://doi.org/10.1038/mtna.2016.53 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical